NSPR
InspireMD, Inc.1.9400
-0.0300-1.52%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
82.20MP/E (TTM)
-Basic EPS (TTM)
-0.82Dividend Yield
0%Recent Filings
8-K
Dearen joins InspireMD board
InspireMD accepted Thomas Kester's board resignation effective September 16, 2025, without disagreements, and swiftly appointed Danny Lee Dearen Jr. as Class III director, Audit Committee chair, and Compensation Committee member that day. Dearen, with deep medtech CFO experience at Axonics and others, received ~$180,000 in equity vesting after one year—or fully if not renominated in 2026. Smooth transition bolsters financial oversight amid U.S. CGuard Prime launch.
8-K
FDA approval, U.S. launch, $58M raise
InspireMD secured FDA PMA approval for CGuard Prime and launched it commercially in the U.S., while raising $58 million in gross proceeds from equity placement and warrants. Q2 revenue edged up 2.3% to $1.778 million, yet operating expenses surged 55.2% to $13.332 million on sales force buildup, driving net loss to $13.151 million. Cash dropped to $19.374 million. Europe launch awaits CE Mark.
10-Q
Q2 FY2025 results
InspireMD posted Q2 revenues of $1.8M, up 2% y/y yet flat q/q (derived), with gross profit dipping to $0.3M from $0.3M as margins held near 18%. Operating expenses doubled to $13.3M on ramped selling/marketing and R&D, driving operating loss to $13.0M from $8.3M y/y; net loss widened to $13.2M, or $(0.26) per diluted share on 51M shares, with the gap to operating tied to financial expense. Cash burned $17.1M in operations, leaving $11.5M plus $7.9M marketable securities at quarter-end, no debt. FDA PMA approval for CGuard Prime spurred U.S. launch and Series I warrant exercises. Cash is tight. Geopolitical risks in Israel loom large.
8-K
InspireMD raises $58M in equity
InspireMD signed a $40.1M private placement on July 30, 2025, for 6.8M shares and pre-funded warrants to buy 9.8M more shares at $2.42 each, closing August 1; separately, Series I warrants fully exercised July 31 for $17.9M, yielding 2.4M shares and 10.6M pre-funded warrants. Board expanded to add medtech veteran Ray Cohen effective closing, while two directors exit year-end. Cash influx fuels CGuard Prime launch post-FDA nod, yet dilutes shareholders.
8-K
U.S. CGuard Prime launch
InspireMD launched CGuard Prime carotid stent system commercially in the U.S. on July 9, 2025, after FDA PMA approval. The dual-layer device traps emboli with MicroNet mesh for stroke prevention, boasting the smallest pore size available. U.S. expansion follows double-digit market share in over 30 countries. Team primed for impact.
CVRX
CVRx, Inc.
8.32+0.14
EW
Edwards Lifesciences Corporatio
85.32+1.94
IINN
Inspira Technologies Oxy B.H.N.
1.02-0.03
INSP
Inspire Medical Systems, Inc.
115.51-3.75
IRMD
iRadimed Corporation
96.87-0.15
IRME
IR-Med Inc.
0.02-0.01
MDNC
MEDINOTEC INC
5.00+0.00
PEN
Penumbra, Inc.
308.10-1.05
VMD
Viemed Healthcare, Inc.
7.26-0.11
VTAK
Catheter Precision, Inc.
2.19-0.04